Book contents
- A Clinician’s Guide to Cannabinoid Science
- Reviews
- A Clinician’s Guide to Cannabinoid Science
- Copyright page
- Dedication
- Contents
- Preface
- Section 1 An Introduction to Cannabinoid Science
- Section 2 Potential Therapeutic Uses of Cannabinoids in Clinical Practice
- Chapter 6 Cannabinoids and Pain
- Chapter 7 Cannabinoids and Neuropsychiatry
- Chapter 8 Cannabinoids in Sleep and Circadian Rhythms
- Chapter 9 Cannabinoids and Inflammation and Autoimmune Disorders
- Chapter 10 Cannabinoids and the Eye
- Chapter 11 Cannabinoids and the Skin
- Index
- References
Chapter 10 - Cannabinoids and the Eye
from Section 2 - Potential Therapeutic Uses of Cannabinoids in Clinical Practice
Published online by Cambridge University Press: 12 October 2020
Book contents
- A Clinician’s Guide to Cannabinoid Science
- Reviews
- A Clinician’s Guide to Cannabinoid Science
- Copyright page
- Dedication
- Contents
- Preface
- Section 1 An Introduction to Cannabinoid Science
- Section 2 Potential Therapeutic Uses of Cannabinoids in Clinical Practice
- Chapter 6 Cannabinoids and Pain
- Chapter 7 Cannabinoids and Neuropsychiatry
- Chapter 8 Cannabinoids in Sleep and Circadian Rhythms
- Chapter 9 Cannabinoids and Inflammation and Autoimmune Disorders
- Chapter 10 Cannabinoids and the Eye
- Chapter 11 Cannabinoids and the Skin
- Index
- References
Summary
In this chapter we will review selected preclinical and clinical information for future development of cannabinoids in the treatment of the eye. Cannabinoids potentially hold great promise for future therapeutic uses, but the clinical knowledge remains too limited to arrive at positive recommendations at this time. Despite the anecdotal reports and interesting findings reported over the past few decades, the US Food and Drug Administration (FDA), Canada Health and the European Medicines Agency (EMA) have yet to approve any cannabinoid for use in the treatment of eye disease.
- Type
- Chapter
- Information
- A Clinician's Guide to Cannabinoid Science , pp. 125 - 136Publisher: Cambridge University PressPrint publication year: 2020
References
Alshaarawy, O. and Elbaz, H. A. (2016) ‘Cannabis use and blood pressure levels’, Journal of Hypertension, 34(8), 1507–1512. doi:10.1097/HJH.0000000000000990.Google Scholar
Barber, A. J., Gardner, T. W. and Abcouwer, S. F. (2011) ‘The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy’, Investigative Ophthalmology and Visual Science, 52(2), 1156–1163. doi:10.1167/iovs.10-6293.CrossRefGoogle Scholar
Ben-Shabat, S. et al. (1998) ‘An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity’, European Journal of Pharmacology, 353(1), 23–31. doi:10.1016/S0014-2999(98)00392-6.Google Scholar
Bouskila, J. et al. (2016) ‘A comparative analysis of the endocannabinoid system in the retina of mice, tree shrews, and monkeys’, Neural Plasticity, 2016, 3127658. doi:10.1155/2016/3127658.Google Scholar
Carlisle, S. J. et al. (2002) ‘Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation’, International Immunopharmacology, 2(1), 69–82. doi:10.1016/S1567-5769(01)00147-3.CrossRefGoogle ScholarPubMed
Caterina, M. J. et al. (1997) ‘The capsaicin receptor: a heat-activated ion channel in the pain pathway’, Nature, 389, 816–824.CrossRefGoogle ScholarPubMed
Chen, J. et al. (2005) ‘Finding of endocannabinoids in human eye tissues: implications for glaucoma’, Biochemical and Biophysical Research Communications, 330(4), 1062–1067. doi:10.1016/j.bbrc.2005.03.095.CrossRefGoogle ScholarPubMed
Chen, M. et al. (2019) ‘Immune regulation in the aging retina’, Progress in Retinal and Eye Research, 69, 159–172. doi:10.1016/j.preteyeres.2018.10.003.Google Scholar
Cooler, P. and Gregg, J. M. (1977) ‘Effect of delta-9-tetrahydrocannabinol on intraocular pressure in humans’, Southern Medical Journal, 70(8), 951–954. doi:10.1097/00007611-197708000-00016.CrossRefGoogle ScholarPubMed
Derocq, J.-M. et al. (1998) ‘The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines’, FEBS Letters, 425(3), 419–425. doi:10.1016/S0014-5793(98)00275-0.Google Scholar
El-Remessy, A. B. et al. (2006) ‘Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes’, American Journal of Pathology, 168(1), 235–244. doi:10.2353/ajpath.2006.050500.Google Scholar
Flom, M. C., Adams, A. J. and Jones, R. T. (1975) ‘Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon?’, Investigative Ophthalmology, 14(1), 52–55.Google ScholarPubMed
Green, K. and Kim, K. (1976) ‘Mediation of ocular tetrahydrocannabinol effects by adrenergic nervous system’, Experimental Eye Research, 23(4), 443–448. doi:10.1016/0014-4835(76)90173-1.Google Scholar
Green, K., Wynn, H. and Bowman, K. A. (1978) ‘A comparison of topical cannabinoids on intraocular pressure’, Experimental Eye Research, 27(2), 239–246. doi:10.1016/0014-4835(78)90092-1.CrossRefGoogle ScholarPubMed
Hampson, A. J. et al. (1998) ‘Cannabidiol and (-)Δ9-tetrahydrocannabinol are neuroprotective antioxidants’, Proceedings of the National Academy of Sciences of the United States of America, 95(14), 8268–8273. doi:10.1073/pnas.95.14.8268.Google Scholar
Hepler, R. S. and Frank, I. R. (1971) ‘Marihuana smoking and intraocular pressure’, JAMA: The Journal of the American Medical Association, 217(10), 1392. doi:10.1001/jama.217.10.1392c.CrossRefGoogle ScholarPubMed
Jager, R. D., Mieler, W. F. and Miller, J. W. (2008) ‘Age-related macular degeneration’, New England Journal of Medicine, 358(24), 2606. doi:10.1056/NEJMra0801537.CrossRefGoogle ScholarPubMed
Katona, I. (2015) ‘Cannabis and endocannabinoid signaling in epilepsy’, Handbook of Experimental Pharmacology, 231, 285–316. doi:10.1007/978-3-319-20825-1_10.Google Scholar
Kauppinen, A. et al. (2016) ‘Inflammation and its role in age-related macular degeneration’, Cellular and Molecular Life Sciences, 73(9), 1765–1786. doi:10.1007/s00018-016-2147-8.CrossRefGoogle ScholarPubMed
Kokona, D. et al. (2016) ‘Endogenous and synthetic cannabinoids as therapeutics in retinal disease’, Neural Plasticity, 2016, 8373020. doi:10.1155/2016/8373020.CrossRefGoogle ScholarPubMed
Kokona, D. and Thermos, K. (2015) ‘Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: involvement of PI3K/Akt and MEK/ERK signaling pathways’, Experimental Eye Research, 136, 45–58. doi:10.1016/j.exer.2015.05.007.Google Scholar
Leske, M. C. (2002) ‘Incident open-angle glaucoma and blood pressure’, Archives of Ophthalmology, 120(7), 954. doi:10.1001/archopht.120.7.954.CrossRefGoogle ScholarPubMed
López, A. et al. (2018) ‘Cannabinoid CB2 receptors in the mouse brain: Relevance for Alzheimer’s disease’, Journal of Neuroinflammation, 15(1), 158. doi:10.1186/s12974-018-1174-9.CrossRefGoogle ScholarPubMed
Matias, I. et al. (2006) ‘Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration’, Prostaglandins, Leukotrienes, and Essential Fatty Acids, 75(6), 413–418. doi:10.1016/j.plefa.2006.08.002.Google Scholar
McPartland, J. M. et al. (2006) ‘Evolutionary origins of the endocannabinoid system’, Gene, 370(1–2), 64–74. doi:10.1016/j.gene.2005.11.004.CrossRefGoogle ScholarPubMed
Merritt, J. C., Crawford, W. J. and Alexander, P. C. (1980) ‘Effect of marihuana on intraocular and blood pressure in glaucoma’, Ophthalmology, 87(3), 222–228. doi:10.1016/s0161-6420(80)35258-5.Google Scholar
Molina-Holgado, F. et al. (2002) ‘Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures’, Journal of Neuroscience Research, 67(6), 829–836. doi:10.1002/jnr.10165.Google Scholar
Nowak, J. Z. (2006) ‘Age-related macular degeneration (AMD): pathogenesis and therapy’, Pharmacological Reports, 58(3), 353–363.Google ScholarPubMed
Porcella, A. et al. (1998) ‘Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana’, Molecular Brain Research, 58(1–2), 240–245. doi:10.1016/S0169-328X(98)00105-3.Google Scholar
Porcella, A. et al. (2000) ‘The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein’, European Journal of Neuroscience, 12(3), 1123–1127. doi:10.1046/j.1460-9568.2000.01027.x.Google Scholar
Rapino, C. et al. (2017) ‘Neuroprotection by (endo)cannabinoids in glaucoma and retinal neurodegenerative diseases’, Current Neuropharmacology, 16(7), 959–970. doi:10.2174/1570159x15666170724104305.Google Scholar
Russo, E. B. et al. (2004) ‘Cannabis improves night vision: a case study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif mountains of northern Morocco’, Journal of Ethnopharmacology, 93(1), 99–104. doi:10.1016/j.jep.2004.03.029.CrossRefGoogle ScholarPubMed
Sakamoto, K. et al. (2014) ‘Activation of the TRPV1 channel attenuates N-methyl-d-aspartic acid-induced neuronal injury in the rat retina’, European Journal of Pharmacology, 733(1), 13–22. doi:10.1016/j.ejphar.2014.03.035.CrossRefGoogle ScholarPubMed
Schwitzer, T. et al. (2015) ‘The cannabinoid system and visual processing: a review on experimental findings and clinical presumptions’, European Neuropsychopharmacology, 25(1), 100–112. doi:10.1016/j.euroneuro.2014.11.002.Google Scholar
Stamer, W. D. et al. (2001) ‘Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues’, European Journal of Pharmacology, 431(3), 277–286. doi:10.1016/S0014-2999(01)01438-8.Google Scholar
Straiker, A. et al. (1999a) ‘Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system’, Proceedings of the National Academy of Sciences of the United States of America, 96(25), 14565–14570. doi:10.1073/pnas.96.25.14565.Google Scholar
Straiker, A. J. et al. (1999b) ‘Localization of cannabinoid CB1 receptors in the human anterior eye and retina’, Investigative Ophthalmology and Visual Science, 40(10), 2442–2448.Google Scholar
Wei, Y., Wang, X. and Wang, L. (2009) ‘Presence and regulation of cannabinoid receptors in human retinal pigment epithelial cells’, Molecular Vision, 15, 1243–1251.Google Scholar
Zhao, D. et al. (2014) ‘The association of blood pressure and primary open-angle glaucoma: a meta-analysis’, American Journal of Ophthalmology, 158(3), 615.e9–627.e9. doi:10.1016/j.ajo.2014.05.029.Google Scholar
Zhong, L. et al. (2005) ‘CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility’, Investigative Ophthalmology and Visual Science, 46(6), 1988–1992. doi:10.1167/iovs.04-0651.CrossRefGoogle ScholarPubMed
- 1
- Cited by